Literature DB >> 6108592

A single dose study of nabilone, a synthetic cannabinoid.

R M Glass, E H Uhlenhuth, F W Hartel, C R Schuster, M W Fischman.   

Abstract

The effects of single oral doses of nabilone, a synthetic cannabinoid, were studied in four anxious volunteer subjects. Each subject had two exposures to placebo and three dose levels of nabilone at 1 week intervals in a single blind balanced Latin square design after the nabilone dose range was determined by each subject's response to a test dose. The Profile of Mood States (POMS), a self-rating adjective checklist, was used as the quantitative measure of subjective effects. The subjects performed a continuous avoidance procedure. High doses (4 or 5 mg) of nabilone produced orthostatic hypotension. Small dose-related increases in heart rate also occurred. Despite the occurrence of highly significant levels of subjective sedation, there were no significant effects of nabilone on behavior maintained by the continuous avoidance procedure. Two of these subjects experienced an anti-anxiety effect from low (1 or 2 mg) nabilone doses, but there was no statistically significant effect on the mean POMS anxiety factor for the group as a whole. In a follow-up experiment, four other anxious subjects received comparatively lower doses of nabilone. In these subjects there were no important effects on blood pressure or heart rate, and also no anti-anxiety effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108592     DOI: 10.1007/bf00434401

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Effects of chlorpromazine on avoidance and escape responding in humans.

Authors:  M W Fischman; R C Smith; C R Schuster
Journal:  Pharmacol Biochem Behav       Date:  1976-01       Impact factor: 3.533

2.  A model for evaluation of antianxiety drugs with the use of experimentally induced stress: Comparison of nabilone and diazepam.

Authors:  S Nakano; H K Gillespie; L E Hollister
Journal:  Clin Pharmacol Ther       Date:  1978-01       Impact factor: 6.875

Review 3.  The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions.

Authors:  L R Derogatis; R S Lipman; K Rickels; E H Uhlenhuth; L Covi
Journal:  Mod Probl Pharmacopsychiatry       Date:  1974

4.  Symptomatic volunteers: another patient dimension for clinical trials.

Authors:  B Brauzer; B J Goldstein
Journal:  J Clin Pharmacol New Drugs       Date:  1973 Feb-Mar

Review 5.  Cannabis: neural mechanisms and behavior--a theoretical review.

Authors:  W G Drew; L L Miller
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

6.  Differentiating depressed from anxious neurotic outpatients.

Authors:  B Prusoff; G L Klerman
Journal:  Arch Gen Psychiatry       Date:  1974-03

7.  Interaction of physostigmine and delta-9-tetrahydrocannabinol in man.

Authors:  F R Freemon; J E Rosenblatt; M K EL-Yousef
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

8.  The effects of chlorpromazine and pentobarbital on behavior maintained by electric shock or point loss avoidance in humans.

Authors:  M W Fischman; C R Schuster
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

9.  Clinical pharmacology of nabilone, a cannabinol derivative.

Authors:  L Lemberger; H Rowe
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

10.  The neurophysiological basis of the marijuana experience.

Authors:  M D Low; H Klonoff; A Marcus
Journal:  Can Med Assoc J       Date:  1973-01-20       Impact factor: 8.262

View more
  9 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

2.  Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2011-01-11       Impact factor: 4.492

Review 3.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

4.  Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2011-10-04       Impact factor: 4.492

Review 5.  Nabilone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; B Holmes
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

6.  Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.

Authors:  Michael J Wesley; Philip M Westgate; William W Stoops; Thomas H Kelly; Lon R Hays; Joshua A Lile
Journal:  Exp Clin Psychopharmacol       Date:  2018-06       Impact factor: 3.157

Review 7.  Cannabinoids in health and disease.

Authors:  Natalya M Kogan; Raphael Mechoulam
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

Review 8.  Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis.

Authors:  Marco Bortolato; Valentina Bini; Simone Tambaro
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-26

Review 9.  Effects of ∆9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies.

Authors:  Ana Maria Raymundi; Thiago R da Silva; Jeferson M B Sohn; Leandro J Bertoglio; Cristina A Stern
Journal:  BMC Psychiatry       Date:  2020-08-26       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.